Earnings Releases·Nov 9, 2026, 4:08 PM ET

OraSure Technologies — Third Quarter 2026 Earnings Summary

Total net revenues grew 14% year-over-year to $30.9 million in Q3 2026, with core business revenues also up 14%; full-year 2026 revenue guidance implies a 4.7% year-over-year growth rate at the midpoint.
GAAP operating loss narrowed to $13.0 million from $16.1 million in the prior year period, while GAAP gross margin improved to 45.2% from 43.5%, driven by operational efficiency initiatives.
Management expects an acceleration of year-over-year total revenue growth in 2027 compared to 2026, supported by initial orders for the Colli-Pee® Dx Urine Collection Kit and OraQuick® Ebola 2.0 Rapid Antigen Test.
The company repurchased $7.0 million of common stock during the nine months ended September 30, 2026, and holds $148.2 million in cash and cash equivalents as of quarter-end.